## Raffaele Manna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7928095/publications.pdf

Version: 2024-02-01

172457 175258 3,303 143 29 52 citations h-index g-index papers 150 150 150 3637 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Transitional care management in patients with auto-inflammatory diseases: experience of cooperation of a paediatric and adult centre. Journal of Transition Medicine, 2022, 4, .	0.5	o
2	Rapid resolution of severe pericardial effusion using anakinra in a patient with COVID-19 vaccine-related acute pericarditis relapse: a case report. European Heart Journal - Case Reports, 2022, 6, ytac123.	0.6	5
3	Coronary Microvascular Dysfunction IsÂAssociated With a Worse Cardiac Phenotype in Patients With Fabry Disease. JACC: Cardiovascular Imaging, 2022, 15, 1518-1520.	5.3	3
4	Evidence of evolution towards left midventricular obstruction in severe Anderson–Fabry cardiomyopathy. ESC Heart Failure, 2021, 8, 725-728.	3.1	8
5	Early introduction of anakinra improves acute pericarditis and prevents tamponade in Staphylococcal sepsis. Internal and Emergency Medicine, 2021, 16, 1391-1394.	2.0	4
6	Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders. CKJ: Clinical Kidney Journal, 2021, 14, 1488-1490.	2.9	3
7	Right ventricular strain in Anderson-Fabry disease. International Journal of Cardiology, 2021, 330, 84-90.	1.7	10
8	The everchanging framework of autoinflammation. Internal and Emergency Medicine, 2021, 16, 1759-1770.	2.0	13
9	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. Rheumatology, 2021, 60, 5705-5712.	1.9	4
10	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. Frontiers in Medicine, 2021, 8, 668173.	2.6	6
11	Children and Adults with PFAPA Syndrome: Similarities and Divergences in a Real-Life Clinical Setting. Advances in Therapy, 2021, 38, 1078-1093.	2.9	15
12	The Use of Chitotriosidase as a Marker of Active Sarcoidosis and in the Diagnosis of Fever of Unknown Origin (FUO). Journal of Clinical Medicine, 2021, 10, 5283.	2.4	6
13	Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 51-58.	0.8	О
14	Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clinical and Experimental Rheumatology, 2021, 39, 51-58.	0.8	2
15	Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e20200059.	1.3	2
16	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-⟨i⟩α⟨ i⟩ Receptorâ€"Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-12.	3.0	24
17	Prognostic significance of right ventricular hypertrophy and systolic function in Anderson–Fabry disease. ESC Heart Failure, 2020, 7, 1605-1614.	3.1	14
18	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-6.	3.0	7

#	Article	IF	CITATIONS
19	Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. Frontiers in Immunology, 2020, 11, 865.	4.8	48
20	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	2.6	21
21	Pediatric Motor Inflammatory Neuropathy: The Role of Antiphospholipid Antibodies. Brain Sciences, 2020, 10, 156.	2.3	0
22	Therapeutic management of idiopathic recurrent serositis: a retrospective study. European Review for Medical and Pharmacological Sciences, 2020, 24, 3352-3359.	0.7	4
23	Mesothelioma in Familial Mediterranean Fever With Colchicine Intolerance: A Case Report and Literature Review. Frontiers in Immunology, 2020, 11, 889.	4.8	8
24	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. Frontiers in Pharmacology, 2019, 10, 918.	3.5	25
25	Long-term treatment with anakinra and canakinumab resolves patellar subchondral erosion in neonatal-onset multisystem inflammatory disease. Reumatismo, 2019, 71, 53-55.	0.9	1
26	FAMILIAL MEDITERRANEAN FEVER: ASSESSING THE OVERALL CLINICAL IMPACT AND FORMULATING TREATMENT PLANS. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019027.	1.3	31
27	Macular Impairment in Fabry Disease: A Morpho-functional Assessment by Swept-Source OCT Angiography and Focal Electroretinography., 2019, 60, 2667.		23
28	Massive Coronary Microvascular Dysfunction in Severe Anderson-Fabry Disease Cardiomyopathy. Circulation: Cardiovascular Imaging, 2019, 12, e009104.	2.6	8
29	Rare missense variants in the ALPK1 gene may predispose to periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. European Journal of Human Genetics, 2019, 27, 1361-1368.	2.8	21
30	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	3.5	35
31	AB1305â€EVALUATION OF SERUM LEVELS OF ASC FOR THE DIAGNOSIS AND MONITORING OF CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES (CAPS). , 2019, , .		0
32	Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two) Tj ETQq0 0 0 2018, 481, 25-33.	rgBT /Ove 1.1	erlock 10 Tf 5 13
33	Coronary Artery Aneurysms Presenting as Acute Coronary Syndrome: An Unusual Case of IgG4-Related Disease Vascular Involvement. Canadian Journal of Cardiology, 2018, 34, 1088.e7-1088.e10.	1.7	13
34	Non-specific gastrointestinal features: Could it be Fabry disease?. Digestive and Liver Disease, 2018, 50, 429-437.	0.9	28
35	Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrology Dialysis Transplantation, 2018, 33, 318-323.	0.7	21
36	Do we understand the pathophysiology of gastrointestinal symptoms in patients with Fabry disease?. Molecular Genetics and Metabolism, 2018, 123, S63.	1.1	0

#	Article	IF	CITATIONS
37	Clinical hints to diagnosis of attenuated forms of Mucopolysaccharidoses. Italian Journal of Pediatrics, 2018, 44, 132.	2.6	25
38	Proposal of a rating scale to recognize Fabry disease in patients with nonspecific gastrointestinal symptoms. Molecular Genetics and Metabolism, 2018, 123, S63-S64.	1.1	0
39	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	2.2	64
40	Resolution of femoral metaphyseal dysplasia in CINCA syndrome after long-term treatment with interleukin-1 blockade. Clinical Rheumatology, 2018, 37, 2007-2009.	2.2	7
41	Use of Intravenous Immunoglobulin Therapy at Unconventional Doses in Refractory Fulminant Systemic Lupus Erythematosus. European Journal of Case Reports in Internal Medicine, 2018, 5, 1.	0.4	3
42	Right Ventricular Hypertrophy, Systolic Function, and Disease Severity in Anderson-Fabry Disease: An Echocardiographic Study. Journal of the American Society of Echocardiography, 2017, 30, 282-291.	2.8	31
43	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. Internal and Emergency Medicine, 2017, 12, 1059-1067.	2.0	7
44	Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group. Molecular Genetics and Metabolism Reports, 2017, 12, 85-91.	1.1	20
45	Kidney involvement in the Schnitzler syndrome, a rare disease. CKJ: Clinical Kidney Journal, 2017, 10, 723-727.	2.9	6
46	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	3.5	89
47	Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome. Frontiers in Immunology, 2017, 8, 1018.	4.8	37
48	Small Intestinal Bacterial Overgrowth Affects the Responsiveness to Colchicine in Familial Mediterranean Fever. Mediators of Inflammation, 2017, 2017, 1-6.	3.0	14
49	Anderson-Fabry's Disease: A Rare but Treatable Case of Fever of Unknown Origin. European Journal of Case Reports in Internal Medicine, 2017, 2, 000645.	0.4	0
50	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	3.5	72
51	Switch from anakinra to canakinumab in a severe case of CINCA syndrome. International Journal of Rheumatic Diseases, 2016, 19, 1354-1356.	1.9	3
52	The impact of fever/hyperthermia in the diagnosis of Fabry: A retrospective analysis. European Journal of Internal Medicine, 2016, 32, 26-30.	2.2	9
53	A position for tumor necrosis factor inhibitors in the management of colchicine-resistant familial Mediterranean fever?. Immunology Letters, 2016, 180, 77-78.	2.5	6
54	Scleroderma and liver disease: a case of an association with primary sclerosing cholangitis. Scandinavian Journal of Rheumatology, 2016, 45, 334-335.	1.1	2

#	Article	IF	Citations
55	Intravenous immunoglobulin for Pediatric Neuropsychiatric Lupus Triggered by Epstein-Barr Virus Cerebral Infection. Israel Medical Association Journal, 2016, 18, 763-766.	0.1	О
56	Colchicine trial in PFAPA Syndrome and MEFV-negative patients. Pediatric Rheumatology, 2015, 13, .	2.1	2
57	PFAPA syndrome as an hereditary autoinflamatory disorder. Pediatric Rheumatology, 2015, 13, .	2.1	0
58	Epidemiology of FMF Worldwide. Rare Diseases of the Immune System, 2015, , 81-90.	0.1	3
59	Autoinflammatory diseases: a possible cause of thrombosis?. Thrombosis Journal, 2015, 13, 19.	2.1	14
60	Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea. Lupus, 2014, 23, 1449-1451.	1.6	13
61	IL- $1\hat{l}^2$ Biological Treatment of Familial Mediterranean Fever. Clinical Reviews in Allergy and Immunology, 2013, 45, 117-130.	6.5	52
62	Human papillomavirus vaccine and systemic lupus erythematosus. Clinical Rheumatology, 2013, 32, 1301-1307.	2.2	98
63	Systemic Complications of Esophageal Lichen Planus. International Journal of Immunopathology and Pharmacology, 2013, 26, 575-578.	2.1	2
64	Haemophagocytic Syndrome Associated with Mucormycosis Infection. International Journal of Immunopathology and Pharmacology, 2012, 25, 751-755.	2.1	4
65	Anti-& Amp; beta; -Adrenoceptors Autoimmunity Causing `ldiopathic' Arrhythmias and Cardiomyopathy. Circulation Journal, 2012, 76, 1345-1353.	1.6	27
66	Familial Mediterranean fever: New phenotypes. Autoimmunity Reviews, 2012, 12, 31-37.	5.8	83
67	Quantifying the efficacy of influenza vaccines. Lancet Infectious Diseases, The, 2012, 12, 659-660.	9.1	2
68	Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus, 2012, 21, 153-157.	1.6	61
69	Fabry disease: polymorphic haplotypes and a novel missense mutation in the <i>GLA</i> gene. Clinical Genetics, 2012, 81, 224-233.	2.0	28
70	Polymyalgia rheumatica in 2011. Best Practice and Research in Clinical Rheumatology, 2012, 26, 91-104.	3.3	19
71	Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: Comparing different experiences. Journal of Dermatology, 2012, 39, 888-889.	1.2	2
72	Severe Giant Cell Arteritis Associated with Essential Thrombocythaemia. International Journal of Immunopathology and Pharmacology, 2010, 23, 1271-1274.	2.1	3

#	Article	IF	CITATIONS
73	Effectiveness of Colchicine Therapy in 4 Cases of Retroperitoneal Fibrosis Associated with Autoinflammatory Diseases. Journal of Rheumatology, 2010, 37, 1971-1972.	2.0	7
74	Association between Familial Mediterranean Fever and Retroperitoneal Fibrosis: Retroperitoneal Fibrosis Regression after Colchicine Therapy. International Journal of Immunopathology and Pharmacology, 2009, 22, 521-524.	2.1	9
75	Familial Mediterranean Fever: A review for clinical management. Joint Bone Spine, 2009, 76, 227-233.	1.6	99
76	La maladie périodique. Revue Du Rhumatisme (Edition Francaise), 2009, 76, 382-389.	0.0	1
77	Efficacy of etanercept in the treatment of a patient with Behçet's disease. Clinical Rheumatology, 2008, 27, 933-936.	2.2	27
78	Wegener's granulomatosis: an update on diagnosis and therapy. Expert Review of Clinical Immunology, 2008, 4, 481-495.	3.0	3
79	Fecal Calprotectin in First-Degree Relatives of Patients with Ulcerative Colitis. American Journal of Gastroenterology, 2007, 102, 132-136.	0.4	29
80	Autoinflammatory gene mutations in Behcet's disease. Annals of the Rheumatic Diseases, 2007, 66, 832-834.	0.9	63
81	Serum macrophage migration inhibitory factor (MIF) in the intercritical phase of hereditary periodic fevers and its relationship with theMIFâ€173G/C polymorphism. Scandinavian Journal of Rheumatology, 2007, 36, 307-310.	1.1	6
82	Management and treatment of lactose malabsorption. World Journal of Gastroenterology, 2006, 12, 187.	3.3	159
83	Psychiatric Manifestations as a Primary Symptom in Antiphospholipid Syndrome. International Journal of Immunopathology and Pharmacology, 2006, 19, 915-917.	2.1	9
84	Sjogren's Syndrome in a Celiac Patient: Searching for Environmental Triggers. International Journal of Immunopathology and Pharmacology, 2006, 19, 445-448.	2.1	9
85	Effect of exogenous $\hat{l}^2$ -galactosidase in patients with lactose malabsorption and intolerance: a crossover double-blind placebo-controlled study. European Journal of Clinical Nutrition, 2005, 59, 489-493.	2.9	54
86	Normalisation of High Ca 19-9 Values in Autoimmune Hepatitis after Steroidal Treatment. International Journal of Immunopathology and Pharmacology, 2005, 18, 603-607.	2.1	6
87	Folic acid supplementation during methotrexate treatment: nonsense?. British Journal of Rheumatology, 2005, 44, 563-564.	2.3	2
88	Pharmacological and Clinical Basis of Treatment of Familial Mediterranean Fever (FMF) with Colchicine or Analogues: An Update. Inflammation and Allergy: Drug Targets, 2005, 4, 117-124.	3.1	157
89	Wegener's granulomatosis: A challenging disease for otorhinolaryngologists. Acta Oto-Laryngologica, 2005, 125, 1105-1110.	0.9	21
90	Non-Life-Threatening Sepsis: Report of Two Cases. American Journal of the Medical Sciences, 2004, 327, 275-277.	1.1	4

#	Article	IF	Citations
91	Probiotic Treatment Increases Salivary Counts of Lactobacilli: A Double-Blind, Randomized, Controlled Study. Digestion, 2004, 69, 53-56.	2.3	104
92	Tolerance induction to rofecoxib in a patient with Bartter's syndrome. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 788-789.	5.7	4
93	FMF revisited. European Journal of Human Genetics, 2004, 12, 255-255.	2.8	0
94	Circulating levels of cyclosporin A in inflammatory bowel disease: relationships with lymphocyte inhibition and the age of patients. European Journal of Clinical Pharmacology, 2004, 60, 161-164.	1.9	1
95	Systemic Inflammatory Diseases and Silicone Breast Prostheses: Report of a Case of Adult Still Disease and Review of the Literature. American Journal of the Medical Sciences, 2004, 327, 102-104.	1.1	11
96	Association of Myasthenia Gravis and Antisynthetase Syndrome: A Case Report. International Journal of Immunopathology and Pharmacology, 2004, 17, 395-399.	2.1	17
97	Identification of an autosomal recessive mode of inheritance in paediatric Beh $ ilde{A}$ Set's families by segregation analysis. , 2003, 122A, 115-118.		32
98	Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis and Rheumatism, 2003, 48, 2632-2644.	6.7	173
99	CASE REPORT: A SWOLLEN AND RED EAR. Journal of the American Geriatrics Society, 2003, 51, 138-139.	2.6	0
100	Familial Mediterranean fever is no longer a rare disease in Italy. European Journal of Human Genetics, 2003, 11, 50-56.	2.8	115
101	Clinical Associations of Serum Antiendothelial Cell Antibodies in Patients With Sudden Sensorineural Hearing Loss. Laryngoscope, 2003, 113, 797-801.	2.0	38
102	Early diagnosis and stage-adapted treatment of Wegener's granulomatosis. Journal of Laryngology and Otology, 2003, 117, 208-211.	0.8	7
103	Globus pharyngis: was it a stroke of lightning?. American Journal of Gastroenterology, 2003, 98, 938-939.	0.4	0
104	Allogenic bone marrow transplantation: not a treatment yet for familial Mediterranean fever. Blood, 2003, 102, 409-409.	1.4	13
105	Cryoglobulinaemia: A True Internistic Disease?. International Journal of Immunopathology and Pharmacology, 2003, 16, 33-41.	2.1	6
106	Mitral valve endocarditis caused by streptococcus oralis occurring after upper gastrointestinal endoscopy. American Journal of Gastroenterology, 2002, 97, 2149-2150.	0.4	7
107	Autoimmunity in Sudden Sensorineural Hearing Loss: Possible Role of Anti-endothelial Cell Autoantibodies. Acta Oto-Laryngologica, 2002, 122, 30-33.	0.9	41
108	Mitral valve endocarditis caused by streptococcus oralis occurring after upper gastrointestinal endoscopy. American Journal of Gastroenterology, 2002, 97, 2149-2150.	0.4	0

#	Article	IF	Citations
109	Pharmacokinetics of Cyclosporin Microemulsion in Patients with Inflammatory Bowel Disease. Clinical Pharmacokinetics, 2001, 40, 473-483.	3.5	27
110	Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. American Journal of Medicine, 2001, 111, 163-164.	1.5	43
111	Y688X, the first nonsense mutation in familial Mediterranean fever (FMF). Human Mutation, 2001, 17, 79-79.	2.5	11
112	Antiâ€Endothelial Autoantibodies in Patients With Sudden Hearing Loss. Laryngoscope, 1999, 109, 1084-1087.	2.0	52
113	Delayed Hypersensitivity to Aminopenicillins Is Related to Major Histocompatibility Complex Genes. Annals of Allergy, Asthma and Immunology, 1998, 80, 433-437.	1.0	69
114	Microscopic haematuria: a diagnostic aid in giant-cell arteritis?. Lancet, The, 1997, 350, 1226.	13.7	4
115	Schizophrenic symptoms and SPECT abnormalities in a coeliac patient: regression after a glutenâ€free diet. Journal of Internal Medicine, 1997, 242, 421-423.	6.0	86
116	Leucoencephalitis after recombinant hepatitis B vaccine. Journal of Hepatology, 1996, 24, 764-765.	3.7	5
117	ABO blood groups and cancer of the pancreas. International Journal of Gastrointestinal Cancer, 1990, 6, 81-8.	0.4	40
118	Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays. Diabetologia, 1990, 33, 731-736.	6.3	70
119	Insulin Adsorption to Threeâ€Liter Ethylen Vinyl Acetate Bags during 24â€Hour Infusion. Journal of Parenteral and Enteral Nutrition, 1989, 13, 539-541.	2.6	14
120	Nicotinamide Increases Câ€peptide Secretion in Patients with Recent Onset Type 1 Diabetes. Diabetic Medicine, 1989, 6, 568-572.	2.3	47
121	Massive hepatomegaly following splenectomy for myeloid metaplasia. American Journal of Medicine, 1988, 84, 797.	1.5	3
122	Effect of Fenfluramine on Insulin/Growth Hormone Ratio in Obese Subjects. Pharmacology, 1988, 36, 106-111.	2.2	8
123	Effect of Fenfluramine on Growth Hormone and Prolactin Secretion in Obese Subjects. Hormone Research, 1987, 27, 190-194.	1.8	19
124	Evidence of Extragastric Gastrin Release in Postoperative Ulcer Patients. Experimental and Clinical Endocrinology and Diabetes, 1986, 87, 223-226.	1.2	0
125	The Effect of Lysine Acetylsalicylate on Somatostatin Inhibition of Insulin Secretion Induced by Arginine. Experimental and Clinical Endocrinology and Diabetes, 1986, 88, 119-122.	1.2	0
126	Stimulatory Effect of Pentagastrin on Growth Hormone and Prolactin Secretion in Normal Subjects. Experimental and Clinical Endocrinology and Diabetes, 1986, 88, 334-338.	1.2	3

#	Article	IF	Citations
127	The Role of cAMP and Prostaglandins in Gastric Acid Secretion after Pentagastrin Administration. Experimental and Clinical Endocrinology and Diabetes, 1986, 87, 219-222.	1.2	2
128	Thromboxane production in diabetes mellitus. Research in Clinic and Laboratory, 1986, 16, 539-542.	0.3	2
129	Relapsing polychondritis with severe aortic insufficiency. Clinical Rheumatology, 1985, 4, 474-480.	2.2	17
130	Chronic active hepatitis and Behçet's syndrome. Clinical Rheumatology, 1985, 4, 93-96.	2.2	10
131	Does Secretin Control Insulin Secretion?. Experimental and Clinical Endocrinology and Diabetes, 1984, 84, 81-86.	1.2	0
132	Fibrolamellar Carcinoma of the Liver: The Malignant Counterpart of Focal Nodular Hyperplasia with Oncocytic Change. American Journal of Clinical Pathology, 1984, 81, 521-526.	0.7	98
133	Multiple gated nuclear angiography performed at rest to evaluate left ventricular function in clinically asymptomatic diabetic patients. Nuclear Medicine Communications, 1984, 5, 681-688.	1.1	3
134	Decreased insulin binding to red blood cells in liver cirrhosis. Acta Diabetologica Latina, 1983, 20, 251-256.	0.2	5
135	EPIDERMAL GROWTH FACTOR, SOMATOSTATIN, AND PSORIASIS. Lancet, The, 1983, 321, 65.	13.7	35
136	Adult Respiratory Distress Syndrome. Archives of Internal Medicine, 1981, 141, 268.	3.8	0
137	Association of retroperitoneal fibrosis, proctitis and rectal stenosis. Postgraduate Medical Journal, 1981, 57, 674-676.	1.8	2
138	Somatostatin infusion in liver cirrhosis: Glucagon control of glucose homeostasis. Diabetologia, 1980, 18, 187-191.	6.3	18
139	FETAL ORIGIN OF AMNIOTIC FLUID INSULIN IN THE HUMAN MOTHER. Clinical Endocrinology, 1980, 12, 67-70.	2.4	8
140	GH Secretion in Open-Angle Glaucoma. Ophthalmologica, 1979, 179, 168-172.	1.9	15
141	Insulin and glucagon concentrations in portal and peripheral veins in patients with hepatic cirrhosis. Diabetologia, 1979, 17, 23-28.	6.3	95
142	Effect of somatostatin (SRIF) on plasma glucose and insulin response to glucagon in liver cirrhosis. Acta Diabetologica Latina, 1979, 16, 139-145.	0.2	0
143	Behavior of pancreatic glucagon, insulin, and HGH in liver cirrhosis, after arginine and i.v. glucose. Acta Diabetologica Latina, 1974, 11, 330-339.	0.2	20